Join our Free Newsletter and unlock 50% off AltIndexFree newsletter + 50% offJoin free
45 / 100
AltIndex AI Score
Hold
AI Score · 12-mo trend
Flat over 3 months0% of VNRX’s tracked signals bullish
FundamentalsBullish
TechnicalsBearish
Alternative dataBearish
SentimentBearish
Price$0.21
Year Range$0.21 – $5.7
Market Cap$6.4M
IndustryMedical Devices

What Is VolitionRX’s AI Stock Analysis?

VolitionRX’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks VolitionRX’s momentum in near-real time.

VolitionRX (VNRX) has an AltIndex AI Score of 45/100, currently a Hold signal. The AI Score distills VolitionRX's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.

VolitionRX’s Full AI Analysis

VolitionRX (NYSE: VNRX) is a biotechnology company focused on developing simple, easy-to-use, blood-based diagnostic tests for cancer and other serious diseases. Leveraging its proprietary Nucleosomics® technology, the company seeks to provide early detection assays that can identify various types of cancer, including colorectal, pancreatic, and lung cancer. Among its major product lines are Nu.Q® Vet and Nu.Q® Discover. As part of its mission, VolitionRX aims to revolutionize cancer diagnostics, prioritizing early detection to improve patient outcomes.

Fundamental Analysis

The revenue for the last quarter was $400,000, representing a significant decrease of 59.53% compared to the previous quarter. This decline is indicative of potential operational or market challenges. Year-over-year, the revenue decrease was 1.97%, which still signals some degree of concern but shows less volatility compared to the sequential quarter.

Premium

Keep reading AltIndex’s full AI analysis of VolitionRX — the fundamental, technical and alternative-data breakdown and the recommendation.

Sign up to read the full analysis

What’s Driving VNRX’s AI Score?

Fundamentals

Revenue for the last quarter was $400,000. This represents a decrease of 59.53% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 1.97%, which may be a cause for concern. Net income for the last quarter was $-7.3M. This represents a decrease of 9.92% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 16.58%, which may be a cause for concern. Ebitda for the last quarter was $-1.7M. This is an increase of -70.43% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of -68.69%, suggesting positive year-over-year growth.

See VolitionRX’s earnings and insider transactions.

Technicals

Today's stock price is $0.21. This represents a decrease of 32.26% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 97.74%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $0.23, which is lower than the previous SMA10 of $0.23. This suggests a potential downward trend in price movement. The RSI is 40.1, indicating a neutral condition.

See the full technical analysis and price prediction.

Alternative data

The business outlook among employees at VolitionRX is neutral. VolitionRX has an estimate of 17,000 visitors to their webpage. The number of visitors is down by -48% in the last couple of months, a worrisome trend as this can indicate a loss in customers.

Explore VolitionRX’s job postings, web traffic and app downloads.

Sentiment & social

VolitionRX has 1,200 followers on their Twitter page. The number of followers is down by -0% in the last couple of months, indicating a loss in interest in the company.

Track VolitionRX’s market sentiment.

Frequently Asked Questions: VolitionRX AI Stock Analysis

VolitionRX's AltIndex AI Score is 45/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.

AltIndex's AI Score model rates VolitionRX a Hold (45/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.

The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.

AltIndex generates a complete written AI analysis of VolitionRX — company overview, fundamentals, technicals and alternative data, with a recommendation. See the VNRX AI Score or sign up to read the full thesis.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.